Table 1 Adalimumab RA clinical safety database.

	Patients	Exposure (PYs)
US regulatory safety update,
31 August 2002
Adalimumab	2468	4870
Placebo	832	365
Through 15 April 2005
Open label extension studies	2504	8047
Act	936	208
ReAct	6610	4251
Total	10 050	12 506

Act, Access to Therapy trial; PY, patient‐years; ReAct, Research in Active RA trial.